Note: Sample below may appear distorted but all corresponding word document files contain proper formattingExcerpt from Term Paper:
This relationship has an effect on the payment rates that CMS sets. Higher cost pharmaceutical therapies are systematically reimbursed below acquisition cost (i.e., the payment system is biased against full reimbursement for higher cost therapies). Reimbursement compared to acquisition cost for the top IO pharmaceuticals by total expenditures indicates that 9 of the 10 are significantly under reimbursed."
Clinical Trials Report:
Congress established Medicare beneficiaries numbering 40 million with a prescription drug coverage, which has been called a "vast expansion of federal support for and control of expenditures on medicines. Even in its early stages, this program is focusing public attention on prescription drug prices, marketing, utilization, and effectiveness." (Weschler, 2004) Further stated in the Clinical Trials report is that, " the Medicare drug benefit is expected to boost prescription drug use by seniors and provide incentives to develop therapies needed by elderly patients such as arthritis, cardiovascular conditions, and Alzheimer's disease. But it also may squeeze prices and profit margins of pharmaceutical companies that sponsor research. A new payment system for oncology treatments and other therapies administered by physicians may alter incentives for R&D in these areas, while the Medicare outpatient pharmacy benefit will establish model formularies, post negotiated prices, promote treatment protocols, and track adverse events and outcomes more thoroughly -- all likely to shape prescribing practices and new product utilization. These developments will require sponsors to incorporate outcomes measures into studies earlier in the development process, and may cause earlier abandonment of unpromising research."
The fall of 2004 was replete with the pharmaceutical industry experiencing one crisis after another as well as for the federal regulators which together managed to raise questions of serious import and "pre and post approval safety testing of new products." (Weschler, 2004) According to the report congress blamed FDA "oversight, accusing agency officials of trying to squelch staff warnings on drug safety issues and of ignoring signs of trouble at Chiron. One response was to call for full disclosure of all clinical trial results by sponsors and FDA -- including those studies that rail to demonstrate efficacy. Investigations were launched into the possibility of manufacturer ethics in behavior and the following issues were considered by government officials and industry leaders":
The nation's adverse event reporting and post marketing surveillance systems are limited and slow to identify looming safety problems *
Sponsors may need to provide much more safety data to bring to market treatments that patients may use for years
DTC advertising for chronic-use drugs may encourage overmedication and unsafe practices
The U.S. vaccine supply system is antiquated and unreliable and needs a major overhaul to prevent shortages and inequitable access
Perhaps regulators and policymakers should rethink efforts over the past decade to accelerate the drug approval process and streamline research requirements. (Weschler, 2004)
Summary and Conclusion:
It is clear that the costs of pharmaceuticals in the United States is too high evidenced in the studies included in this work concerning participation in prescription medication arbitrate on the part of government municipalities, officials as well as individuals throughout the nation in order to better afford the medications that are needed. It is clear that the regulation of drug costs would greatly benefit the American people in their being able to afford necessary and crucial medications for their healthcare. Congress does unfortunately seem to be under the spell of the pharmaceutical companies and this fact demands that something is done to unwind the tie, which binds the U.S. Congress and the pharmaceutical companies. While the Medicare Modernization Act will benefit those who have spent over $3,600 each year on medications, this will effectively bar many from receiving medication after reaching the $2,200 sub-cap amount from ever purchasing medication enough to reach the next level when the requirement is paying 100% in the interim of the two levels. Therefore, it does not appear that this country can afford the new Medicare Modernization Act. There is a great need for restructuring of the Food and Drug Administration whose safety standards have slipped to the almost non-existent point as well as Medicare needing turned around however, it appears that regulation of pharmaceutical costs would be the biggest accomplishment in turning the problems of the pharma industry around.
Krupin, Stephen (2001) Study: Drug Costs Outpace Inflation. The Palm Beach Post; 6/13/2001; Washington Bureau
Congress approves Medicare drug benefit. (the Year in Review November '03) Chain Drug Review; 4/26/2004 Washington, 2004 Racher Press, Inc.
Pssst...Wanna Buy Some Augmentin" Forbes Magazine (2004) May 23, 2004
The Pharmaceutical Industry: From Bad to Awful (2004) the Economist November 27, 2004.
Braid, M. et al. (2004) Pharmaceutical "Charge Compression" under the Medicare Outpatient Prospective Payment System" Journal of Healthcare Finance Volume: 30 Number: 3
ISSN: 10786767 4/2/4002.
Wechsler, Jill (2004) Reimbursement and Regulation Shape Pharmaceutical Research: The Medicare Drug Benefit and FDA's Critical Path Initiative will Push and Pull New Drug Development - View from Washington Applied Clinical Trials 12/1/2004
Brink, Susan (2004) Crossing Borders U.S. News…[continue]
"Pharmaceutical Industry The Purpose Of" (2005, March 01) Retrieved October 21, 2016, from http://www.paperdue.com/essay/pharmaceutical-industry-the-purpose-of-62803
"Pharmaceutical Industry The Purpose Of" 01 March 2005. Web.21 October. 2016. <http://www.paperdue.com/essay/pharmaceutical-industry-the-purpose-of-62803>
"Pharmaceutical Industry The Purpose Of", 01 March 2005, Accessed.21 October. 2016, http://www.paperdue.com/essay/pharmaceutical-industry-the-purpose-of-62803
38 per share on the company's common stock for the first quarter of 2005. The dividend is payable January 3, 2005 to stockholders of records at the close of business on December 3, 2004. Growth in the ZETIA and VYTORIN franchises are expected to continue. T There are currently several candidates in Phase III that Merck plans to file in 2005 as well as Type 2 diabetes treatment and three vaccines.
For example, before its paten ran out, "the price of Schering-Plough's top-selling allergy pill, Claritin, was raised thirteen times over fives years, for a cumulative increase of more than 50%, over four times the rate of general inflation." In 2002, the average price of the fifty drugs most used by senior citizens was approximately $1,500 for a year's supply, and although this refers to what the companies call the
Pharmaceutical Ethics Issues Generally, business ethics is a concept that has not been upheld or exemplified to any high standard by the modern pharmaceutical industry. It is an industry frequently plagued by unethical marketing decisions and practices, the pursuit of business strategies and policies that violate public trust in spirit if not necessarily in the written word, and that has embraced research practices that are sometimes highly questionable. In the modern
Corporate Social Responsibility in Indian Pharmaceutical Industry An Exploratory Study Outlook of CSR in India History of CSR in India Philanthropy in Indian Society Modern Form of CSR in Indian Society Profile of Indian Pharmaceutical Industry Rationale for Selection CSR Activities by Indian Pharmaceutical Companies Major Influences Over CSR Activities Scope of CSR Activities Comparison of Indian & Western Pharmaceutical Companies This research paper is concerned with the recent practices of Indian pharmaceutical companies in the field of corporate social responsibility. For
Pfizer The Economics of the Pharmaceutical Industry -- Focus on Pfizer Drugs Specify on some background of the company According to its official website, Pfizer Incorporated "discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known consumer brands. Our innovative, value-added products improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. The company has
pharmaceuticals in Russia. The writer provides an overview of the history of the topic as well as the current concerns in the field. There were five sources used to complete this paper. When the Soviet Union dismantled its communist regime and began to rebuild its entire political and economic structure the world cheered and offered its support. It has been more than a decade and while several areas have been
Ganga Pharmaceuticals is a multinational Indian corporation that competes in the manufacturing of pharmaceuticals and related research and development with annual revenues of about $285 million. The company features one of the largest biotechnology parks in India and currently employs around 7,000 employees globally. In recent years, Ganga has acquired a number of companies in Europe and the United States, including C-Pharma, which was acquired in 2003 for approximately $17.2